Atul Deshpande, PHD, MBA, A-PMP
Chief Strategy Officer
Atul Deshpande, DPM, is the Chief Strategy Officer at Peptilogics, responsible for strategy and business development.
Prior to joining Peptilogics, Atul served as Chief Executive Officer of IMMEDIATE Therapeutics, a clinical stage biotech company dedicated to developing safe and effective therapeutic solutions to reduce heart muscle damage and prevent cardiac arrest in Acute Coronary Syndromes (ACS), the most common cause of death and morbidity across the world. Before working at IMMEDIATE Therapeutics, Atul was the Chief Strategy Officer and Head of US Operations for Harbour BioMed (HBM). Atul was primarily responsible for building the company’s short and long-term strategy and portfolio, along with a robust execution plan. He also oversaw HBM’s operations in both the US and EU to maintain HBM’s footprint across these markets, along with managing key alliances and business development in these regions. In 2020, he aided in taking the company public in the HK stock exchange, raising a total of $400M.
Before HBM, Atul served as the Global Operations Head for the Dupixent Franchise with Sanofi. He led marketing, market access and supply chain, launching Dupixent in several markets. He also led operations for Sanofi’s Immunology R&D portfolio and was responsible for new product planning and in-licensing evaluations. He spent three years in China as the Head of Asia Pacific R&D strategy, to bring the global portfolio to China with minimal drug lag. Before Sanofi, Atul worked for nine years as a management consultant on projects across the value chain of pharma.
Atul holds a Ph.D. from UC Irvine in Neuroscience, post-doc from UCLA and MBA from Cranfield University in the UK.